Johnson & Johnson Presented neoadjuvant TAR-200 plus cetrelimab ... that included treatment with cetrelimab was being discontinued for not showing superiority to chemoradiation during a scheduled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback